Publikasi Scopus 926 artikel (Per 14 Maret 2022)

Saifuddin A., Koesnoe S., Kurniati N., Sirait S., Arisanty R., Yunihastuti E.
57217827222;26028015000;57310154400;56426927400;57204115712;57221273925;
COVID Arm After Moderna Booster in Healthcare Worker: A Case Report
2021
Acta medica Indonesiana
53
3
326
330
3
Division of Allergy and Clinical Immunology, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia - Cipto Mangunkusumo HospitalJakarta, Indonesia
Saifuddin, A., Division of Allergy and Clinical Immunology, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia - Cipto Mangunkusumo HospitalJakarta, Indonesia; Koesnoe, S.; Kurniati, N.; Sirait, S.; Arisanty, R.; Yunihastuti, E.
SARS CoV-2 virus has infected more than 200 million people worldwide and more than 4.4 million in Indonesia. The vaccination program has become one of the solutions launched by many countries globally, including Indonesia, to reduce the transmission rate of COVID-19. Various vaccination platforms are produced, such as inactivated, viral vector, mRNA, and protein subunit. The vaccination booster program with mRNA platform (Moderna) was launched by the Indonesian government to give better protection for health care workers, particularly from delta variant. In this case report, we discuss one of the typical side effects of Moderna vaccine, which is referred to as the COVID arm.
booster; COVID arm; COVID-19; healthcare worker; Moderna; vaccination
analgesic agent; elasomeran; paracetamol; administration and dosage; adverse drug reaction; adverse event; biopsy; case report; delayed hypersensitivity; epidemiology; female; fever; human; injection site reaction; middle aged; pathology; pathophysiology; physician; prevention and control; procedures; skin; treatment outcome; vaccination; Acetaminophen; Analgesics, Non-Narcotic; Biopsy; COVID-19; COVID-19 Vaccines; Drug-Related Side Effects and Adverse Reactions; Female; Fever; Humans; Hypersensitivity, Delayed; Injection Site Reaction; Middle Aged; Physicians; SARS-CoV-2; Skin; Treatment Outcome; Vaccination
NLM (Medline)
01259326
34611073
Article
Q3
321
14162